Torrent Pharmaceuticals has announced a significant fundraising initiative, with its board approving the raising of up to ₹12,500 crore through the issuance of securities on a private placement basis. The pharmaceutical company disclosed this development through a regulatory filing following a board committee meeting held on Monday.

Fundraising Structure and Approval

The Securities Transfer and Stakeholders Relationship Committee has given its approval for the issuance of secured, rated, listed, redeemable non-convertible debentures. The fundraising details are outlined in the following structure:

Recent Corporate Developments

This fundraising announcement follows Torrent Pharma's major acquisition activity from the previous year. In June last year, the company announced its plan to acquire a majority stake in J B Chemicals and Pharmaceuticals through a substantial ₹19,500-crore deal, demonstrating the company's expansion strategy in the pharmaceutical sector.

Market Performance

The company's stock performance on Monday reflected a slight decline, with shares closing the trading session marginally lower:

The fundraising through non-convertible debentures represents a debt financing approach that allows the company to raise capital while maintaining its current equity structure, as these instruments do not convert into equity shares.

Torrent Pharmaceuticals Limited has received credit rating reaffirmation from ICRA Limited, maintaining its strong financial standing in the pharmaceutical sector. The company announced this development through a regulatory filing dated January 5, 2026, in compliance with SEBI disclosure requirements.

Credit Rating Details

ICRA Limited has taken the following rating actions for Torrent Pharmaceuticals:

The reaffirmation of the [ICRA] AA+ (Stable) rating for both banking facilities and NCDs indicates ICRA's continued confidence in the company's creditworthiness and financial stability. The stable outlook suggests that the rating agency expects the company to maintain its current credit profile over the medium term.

Commercial Paper Programme Enhancement

A notable aspect of the rating action is ICRA's decision regarding the commercial paper programme. The rating agency has not only reaffirmed the [ICRA] A1+ rating for the existing amount but has also assigned the same rating for an enhanced amount. This development suggests that Torrent Pharmaceuticals is expanding its short-term funding capabilities while maintaining the highest short-term credit rating category.

Regulatory Compliance

The announcement was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary Chintan M. Trivedi signed the disclosure document, ensuring proper compliance with stock exchange notification requirements for both BSE and NSE, where the company's shares are listed under scrip codes 500420 and TORNTPHARM respectively.

The credit rating reaffirmation reflects positively on Torrent Pharmaceuticals' financial management and operational performance, providing stakeholders with continued confidence in the company's credit quality and debt servicing capabilities.